Slide Source:Lipids Online Slide Librarywww.lipidsonline.org

CDC/AHA Scientific Statement on Inflammatory CDC/AHA Scientific Statement on Inflammatory Markers and Cardiovascular Disease:Markers and Cardiovascular Disease: Recommendations for Population ScienceRecommendations for Population Science

Class III (evidence/agreement that the procedure is not useful/effective and may be harmful), Evidence level C (consensus opinion of experts)

The entire adult population should not be screened for hs-CRP for purposes of cardiovascular risk assessment

Pearson TA et al. Circulation 2003;107:499–511.

Slide Source:Lipids Online Slide Librarywww.lipidsonline.org

CDC/AHA Scientific Statement on Inflammatory CDC/AHA Scientific Statement on Inflammatory Markers and Cardiovascular Disease:Markers and Cardiovascular Disease: Recommendations for Laboratory TestingRecommendations for Laboratory Testing Class IIa (in favor of usefulness), Evidence level B (data

derived from nonrandomized studies) 2 measurements, optimally 2 weeks apart, should be

averaged, in fasting or nonfasting metabolically stable patients. If hs-CRP >10 mg/L, test should be repeated and patient examined for sources of infection or inflammation

hs-CRP risk categories: Low: <1 mg/L Average: 1–3 mg/L High: >3 mg/L

Pearson TA et al. Circulation 2003;107:499–511.

Slide Source:Lipids Online Slide Librarywww.lipidsonline.org

CDC/AHA Scientific Statement on Inflammatory CDC/AHA Scientific Statement on Inflammatory Markers and Cardiovascular Disease:Markers and Cardiovascular Disease: Recommendations for Clinical Practice (I)Recommendations for Clinical Practice (I) Class IIa (in favor of usefulness), Evidence level B (data

derived from nonrandomized studies) In patients at intermediate global risk (10–20%/10 yr),

hs-CRP measurement may help direct evaluation and therapy for primary prevention; benefits uncertain.

Patients with persistent unexplained hs-CRP elevation >10 mg/L should be evaluated for noncardiovascular etiologies.

In patients with stable coronary disease or ACS, hs-CRP may be useful as a marker of prognosis for recurrent events; benefits uncertain.

Pearson TA et al. Circulation 2003;107:499–511.

Slide Source:Lipids Online Slide Librarywww.lipidsonline.org

CDC/AHA Scientific Statement on Inflammatory CDC/AHA Scientific Statement on Inflammatory Markers and Cardiovascular Disease:Markers and Cardiovascular Disease: Recommendations for Clinical Practice (II)Recommendations for Clinical Practice (II)

Class IIb (usefulness less well established), Evidence level B (data derived from nonrandomized studies)

hs-CRP measurement may be used as part of global risk assessment in primary prevention; benefits uncertain.

hs-CRP may improve motivation for lifestyle modification; benefits uncertain.

Pearson TA et al. Circulation 2003;107:499–511.